Presentation of the Centre

IPO Lisboa is a centre with over a century of experience in the treatment, study and research of cancer. Our centre is recognised as the leading reference centre for the diagnosis and treatment of sporadic and hereditary cancers in the south of Portugal, receiving around 6,000 new patients every year. These patients are managed by multidisciplinary teams providing highly specialised and differentiated healthcare. Comprehensive treatment plans, including surgery, radiotherapy, chemotherapy or a combination of therapies, are used to ensure the highest level of care and optimise patient outcomes and quality of life.

Main Research Activities

Dedicated to research in the oncology field, IPO Lisboa has an extensive record of conducting innovative research with a multidisciplinary approach, ranging from basic and translational research to clinical and epidemiological studies, as well as clinical trials. Translational biomedical research focuses on the aggressiveness of cancer, as well as familial and individual cancer risk, including genetics, epigenetics, metabolism, morphology and microenvironment, therapeutic modulation, biomarker identification, and the development of new therapies. Currently, IPO Lisboa’s staff includes 286 professionals dedicated to research activities, including 41 PhD holders, 24 ongoing PhD theses and 19 researchers with a master’s degree.

Core Facilities

IPO Lisboa offers a wide range of clinical and research health services to meet patient needs, which are recognised for their quality and innovation. Clinical: Inpatient services; a wide range of medical specialities in outpatient care; patient day care units; bone marrow and haemopoietic progenitor transplantation; physical medicine and rehabilitation; home care; diagnostic imaging technology; radiotherapy (external beam and brachytherapy); nuclear medicine; Familial Cancer Risk and Prevention Clinic; Molecular Pathobiology; Clinical Pathology and Cytopathology laboratories. Research: Research Centre; Clinical Trial Unit; Tumour Bank (part of the National Network of Tumour Banks); Molecular Tumour Board; Epidemiology Research Unit; Molecular Biology Unit, including Cytometry, Cytogenetics, Microscopy and Molecular Diagnosis; Familial Cancer Risk Clinic (over 18,000 families registered).

Education

IPO Lisboa is an institution accredited by the Ministry of Health for training medical doctors specialising in oncology. It is also recognised for educating and training nurses and other health professionals in oncology.